GSA Capital Partners LLP Purchases New Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

GSA Capital Partners LLP acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 3,790 shares of the biopharmaceutical company’s stock, valued at approximately $217,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Congress Asset Management Co. grew its stake in shares of Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after acquiring an additional 1,988,238 shares in the last quarter. Handelsbanken Fonder AB grew its position in shares of Halozyme Therapeutics by 76.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock worth $112,715,000 after purchasing an additional 856,200 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Halozyme Therapeutics by 12.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after purchasing an additional 209,530 shares during the period. American Century Companies Inc. raised its position in shares of Halozyme Therapeutics by 9.7% in the second quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company’s stock valued at $43,002,000 after buying an additional 72,544 shares in the last quarter. Finally, Federated Hermes Inc. boosted its stake in shares of Halozyme Therapeutics by 37.8% in the second quarter. Federated Hermes Inc. now owns 696,131 shares of the biopharmaceutical company’s stock valued at $36,449,000 after buying an additional 191,030 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

HALO has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $68.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, November 20th. JMP Securities increased their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Benchmark restated a “buy” rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. TD Cowen lifted their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, JPMorgan Chase & Co. cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.11.

Insider Activity

In related news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $59.09, for a total value of $590,900.00. Following the completion of the sale, the chief executive officer now owns 676,744 shares of the company’s stock, valued at approximately $39,988,802.96. This trade represents a 1.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 60,000 shares of company stock worth $3,425,000. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Up 7.2 %

NASDAQ:HALO opened at $49.00 on Monday. Halozyme Therapeutics, Inc. has a 52 week low of $33.15 and a 52 week high of $65.53. The firm’s fifty day moving average is $54.58 and its 200-day moving average is $53.57. The firm has a market cap of $6.23 billion, a P/E ratio of 16.23, a P/E/G ratio of 0.42 and a beta of 1.29. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.